TABLE 2.

Urinary excretion parameters of EFV and metabolites in healthy volunteers after a single 100-mg oral dose of EFV alone (control) and after treatment with voriconazole to steady state

Parameter	Mean ± SD for group:		% mean change	P value
	Control	Voriconazole
Amt (Ae0–48, nmol) recovered in urine over 48 h
EFV	27.0 ± 12.8	36.0 ± 20.3	50.1	<0.001
% dose	0.009 ± 0.004	0.012 ± 0.006		<0.001
8-OHEFV	15,733 ± 6,362	9,334 ± 5,015	−33.3	<0.001
% dose	5.0 ± 2.0	3.0 ± 1.6		<0.001
7-OHEFV	4,030 ± 2,459	3,363 ± 1,501	8.5	<0.01
% dose	1.3 ± 0.8	1.1 ± 0.5		<0.01
Di-OHEFV	11,871 ± 4,803	5,088 ± 3,245	−48.8	<0.001
% dose	3.8 ± 1.5	1.6 ± 1.0		<0.001
8- + di-OHEFV	27,603 ± 10,681	14,422 ± 8,021	−41.1	<0.001
% dose	8.7 ± 3.4	4.6 ± 2.5		<0.001
Total % of dose	10.0 ± 3.9	5.6 ± 2.6		<0.001
CLfa of EFV to metabolite (ml/min)
EFV to 8-OHEFV	558 ± 272	219 ± 209	−61.5	<0.001
% total CLf	49.0 ± 6.4	51.5 ± 7.2	6.2	<0.01
EFV to 7-OHEFV	141 ± 99	74 ± 34	−39.8	<0.001
% total CLf	12.4 ± 5.6	19.8 ± 8.4	70.1	<0.001
8-OHEFV to di-OHEF	1,505 ± 649	940 ± 784	−37.1	<0.001
EFV to 8- + di-OHEFV	996 ± 468	345 ± 349	−66.5	<0.001
% total CLf	87.6 ± 5.6	80.2 ± 8.4	−9.0	<0.001

^aCL_f, 0- to 48-h formation clearance.